Stock data
Alnylam Pharmaceuticals, Inc. (ALNY)
Alnylam Pharmaceuticals, Inc. (ALNY) reported revenue of US$3.71B and net income of US$313.75M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$3.71B | — | US$501.58M | US$313.75M | — |
| 2024 | US$2.25B | — | -US$176.88M | -US$278.16M | — |
| 2023 | US$1.83B | — | -US$282.18M | -US$440.24M | — |
| 2022 | US$1.04B | — | -US$785.07M | -US$1.13B | — |
| 2021 | US$844.29M | — | -US$708.65M | -US$852.82M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$1.29B | US$164.49M | — |
| 2026-03-31 | — | US$205.99M | — |
| 2025-12-31 | US$1.10B | US$153.14M | — |
| 2025-09-30 | US$1.25B | US$251.08M | — |
| 2025-06-30 | US$773.69M | -US$72.23M | — |
| 2025-03-31 | US$594.19M | -US$18.25M | — |
| 2024-12-31 | US$593.17M | -US$83.76M | — |
| 2024-09-30 | US$500.92M | -US$111.57M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.